<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000661991"><TermName>lintuzumab</TermName><TermPronunciation>(lin-TOO-zoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of myelodysplastic syndromes and some types of leukemia. It binds to CD33, a protein on the surface of certain normal blood stem cells and some abnormal blood cells. It causes the immune system to kill these cells. Lintuzumab is a type of monoclonal antibody. Also called MoAb HuM195 and monoclonal antibody HuM195.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000725762" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;lintuzumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000725761" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;lintuzumab&quot;" language="es" id="_4"/><SpanishTermName>lintuzumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de los síndromes mielodisplásicos y algunos tipos de leucemia. Se una a la proteína CD33 en la superficie de algunas células madre y algunos glóbulos sanguíneos anormales. Ocasiona que el sistema inmunitario elimine estas células. El lintuzumab es un tipo de anticuerpo monoclonal. También se llama anticuerpo monoclonal HumM195 y MoAb HuM195.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-04-07</DateFirstPublished></GlossaryTerm>
